Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | STAT6 | P42226 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1301312 | 1.00 | METTL3 (0.45) | METTL3JAK2JAK3GSK3BSTAT6 | |
| SCHEMBL1300337 | 0.91 | METTL3 (0.41) | METTL3JAK2JAK3GSK3BLMNA | |
| SCHEMBL1300334 | 0.91 | METTL3 (0.41) | METTL3JAK2JAK3GSK3BLMNA | |
| SCHEMBL1300644 | 0.91 | METTL3 (0.43) | METTL3JAK3GSK3BLMNAPDE10A | |
| SCHEMBL1301563 | 0.91 | METTL3 (0.45) | METTL3JAK2JAK3GSK3BSTAT6 | |
| SCHEMBL1301560 | 0.91 | METTL3 (0.45) | METTL3JAK2JAK3GSK3BSTAT6 | |
| SCHEMBL1300638 | 0.91 | METTL3 (0.43) | METTL3JAK3GSK3BLMNAPDE10A | |
| SCHEMBL1301707 | 0.90 | METTL3 (0.49) | METTL3GSK3BSTAT6PDE10A | |
| SCHEMBL1301713 | 0.90 | METTL3 (0.49) | METTL3GSK3BSTAT6PDE10A | |
| SCHEMBL1300298 | 0.90 | METTL3 (0.43) | METTL3GSK3BLMNACYP2C9ATP6V1B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885JAK2 4141/4885JAK3 3556/4885 |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885JAK2 4141/4885JAK3 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.